# Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer

> **NCT01715142** · EARLY_PHASE1 · COMPLETED · sponsor: **Jean-Luc Van Laethem** · enrollment: 23 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma Resectable
- Pancreatic Adenocarcinoma Locally Advanced
- Pancreatic Adenocarcinoma Metastatic

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT01715142
- **Lead sponsor:** Jean-Luc Van Laethem
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-21
- **Primary completion:** 2015-09-21
- **Final completion:** 2017-04-30
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01715142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01715142, "Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01715142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*